At the time of writing, Blueprint Medicines Corp [BPMC] stock is trading at $90.50, up 3.12%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BPMC shares have gain 0.65% over the last week, with a monthly amount drifted -12.98%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $150. Previously, JP Morgan started tracking the stock with Overweight rating on November 14, 2024, and set its price target to $126. On October 24, 2024, UBS initiated with a Neutral rating and assigned a price target of $88 on the stock. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $140 on May 14, 2024. Leerink Partners upgraded its rating to a Market Perform and raised its price target to $97 on May 06, 2024. Oppenheimer upgraded its rating to Outperform for this stock on October 27, 2023, but kept the price target unchanged to $85. In a note dated August 21, 2023, Needham reiterated an Buy rating on this stock and boosted its target price from $65 to $66.
For the past year, the stock price of Blueprint Medicines Corp fluctuated between $80.68 and $121.90. Currently, Wall Street analysts expect the stock to reach $132 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $90.50 at the most recent close of the market. An investor can expect a potential return of 45.86% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
According to Blueprint Medicines Corp [NASDAQ:BPMC], the company’s sales were 508.82M for trailing twelve months, which represents an 103.41% jump. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.22 and Total Capital is -0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 87.98 points at the first support level, and at 85.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.87, and for the 2nd resistance point, it is at 93.24.
Ratios To Look Out For
It is important to note that Blueprint Medicines Corp [NASDAQ:BPMC] has a current ratio of 2.85. As well, the Quick Ratio is 2.80, while the Cash Ratio is 0.39. Considering the valuation of this stock, the price to sales ratio is 11.37, the price to book ratio is 19.31.
Transactions by insiders
Recent insider trading involved Hewes L. Becker, CHIEF MEDICAL OFFICER, that happened on Mar 06 ’25 when 5232.0 shares were sold. CHIEF MEDICAL OFFICER, Hewes L. Becker completed a deal on Mar 05 ’25 to sell 4863.0 shares. Meanwhile, CHIEF OPERATING OFFICER Rossi Christina sold 6495.0 shares on Mar 05 ’25.
